Kenjiro Taniguchi

Yonago, 6830006, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Timing of Immune Checkpoint Inhibitor Initiation and Overall Survival in Advanced Gastric Cancer: A Multicenter Real-World Study Using Clone-Censor-Weight Analysis.

Timing of Immune Checkpoint Inhibitor Initiation and Overall Survival in Advanced Gastric Cancer: A Multicenter Real-World Study Using Clone-Censor-Weight Analysis.

Journal: Journal of gastrointestinal cancer

Published: May 15, 2026

Unfavorable Outcomes of T3N0 Remnant Gastric Cancer After Distal Gastrectomy.

Unfavorable Outcomes of T3N0 Remnant Gastric Cancer After Distal Gastrectomy.

Journal: Anticancer research

Published: March 23, 2026

Impact of Postoperative Prognostic Nutritional Index on Post-gastrectomy Outcomes in Older Adults With Gastric Cancer.

Impact of Postoperative Prognostic Nutritional Index on Post-gastrectomy Outcomes in Older Adults With Gastric Cancer.

Journal: Anticancer research

Published: January 10, 2026

Prognostic significance of the C-reactive protein-albumin-lymphocyte index in patients with unresectable or recurrent gastric cancer treated with First-line fluoropyrimidine-based chemotherapy.

Prognostic significance of the C-reactive protein-albumin-lymphocyte index in patients with unresectable or recurrent gastric cancer treated with First-line fluoropyrimidine-based chemotherapy.

Journal: Surgery today

Published: January 04, 2026

Bowel Diameter at the Obturator Canal as a Predictor of Bowel Resection in Incarcerated Obturator Hernias.

Bowel Diameter at the Obturator Canal as a Predictor of Bowel Resection in Incarcerated Obturator Hernias.

Journal: Yonago acta medica

Published: November 18, 2025

Comparison of Postoperative Outcomes of Laparoscopic Versus Open Gastrectomy in Older Patients With Gastric Cancer.

Comparison of Postoperative Outcomes of Laparoscopic Versus Open Gastrectomy in Older Patients With Gastric Cancer.

Journal: Anticancer research

Published: February 10, 2025

Impact of Lymphocyte/Monocyte Ratio on Outcomes in Patients with Remnant Gastric Cancer After Gastrectomy.

Impact of Lymphocyte/Monocyte Ratio on Outcomes in Patients with Remnant Gastric Cancer After Gastrectomy.

Journal: Yonago acta medica

Published: September 19, 2024

Using the geriatric nutritional risk index to predict outcomes in older patients with remnant gastric cancer after gastrectomy: a retrospective multicenter study in Japan.

Using the geriatric nutritional risk index to predict outcomes in older patients with remnant gastric cancer after gastrectomy: a retrospective multicenter study in Japan.

Journal: Surgery today

Published: February 08, 2024

The prognostic impact of the lymphocyte-to-C-reactive protein ratio in patients with unresectable or recurrent advanced gastric cancer treated with first- and second-line treatment.

The prognostic impact of the lymphocyte-to-C-reactive protein ratio in patients with unresectable or recurrent advanced gastric cancer treated with first- and second-line treatment.

Journal: Surgery today

Published: October 03, 2022

A Case of Surgically Treated Primary Anorectal Malignant Melanoma Detected by Colorectal Cancer Screening

A Case of Surgically Treated Primary Anorectal Malignant Melanoma Detected by Colorectal Cancer Screening

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: March 17, 2022

Impact of geriatric nutritional risk index on outcomes after gastrectomy in elderly patients with gastric cancer: a retrospective multicenter study in Japan.

Impact of geriatric nutritional risk index on outcomes after gastrectomy in elderly patients with gastric cancer: a retrospective multicenter study in Japan.

Journal: BMC cancer

Published: March 15, 2022

CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab.

CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab.

Journal: BMC cancer

Published: May 13, 2021

Showing 1-12 of 15

Last Updated: 09/26/2026